Psyence BioMed Forms Texas Ibogaine Unit
Analysis based on 8 articles · First reported Sep 14, 2026 · Last updated Sep 14, 2026
The announcement is a small-cap corporate development for Psyence BioMed and is unlikely to move broad markets, though it may draw speculative interest in psychedelic and neuroplastogen biotech names. The stock reaction is likely modest and company-specific, with execution and licensing risk limiting any sustained re-rating.
Psyence Biomedical Ltd. (Nasdaq: PBM) announced on September 14, 2026 the formation of Texas Ibogaine Research Corporation (TIRC), a Texas-based company established to coordinate the Company's U.S. ibogaine development activities, including pharmaceutical-grade supply, regulatory engagement and potential clinical development. TIRC is intended to serve as Psyence BioMed's dedicated U.S. vehicle for the regulated development of ibogaine. Subject to completion of definitive licensing arrangements, TIRC is positioned to hold U.S. rights to pharmaceutical-grade ibogaine developed by PsyLabs, a neuroplastogen active pharmaceutical ingredient development company in which Psyence BioMed holds an ownership interest. The Company intends for TIRC to coordinate applicable rights, manufacturing arrangements, regulatory documentation and any future investigational new drug application within a single U.S. entity financed by Psyence BioMed, and to serve as counterparty of record in engagements with federal agencies, state programs and potential clinical partners in the United States. Jody Aufrichtig, Chief Executive Officer of Psyence BioMed, will also serve as CEO of TIRC, while Dr. John Thornton has been appointed project lead. Psyence BioMed expects to provide technical, legal, administrative and financial support through existing internal resources, with corporate oversight from Chief Financial Officer Warwick Corden-Lloyd and the in-house legal function. The formation follows U.S. policy and research developments involving neuroplastogens, including an Executive Order signed on April 18, 2026 directing federal agencies to accelerate relevant research, coordinated federal implementation announced in July 2026, and the provision of the University of Miami's original 1994 ibogaine investigational new drug application to the U.S. Department of Health and Human Services. Next steps include completing definitive licensing arrangements, advancing regulatory engagement and developing manufacturing and clinical plans, all subject to applicable laws and regulatory requirements.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard